Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

Group 1 - The company, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., have participated in the national centralized procurement for the continuation of products from the first to eighth batches, with results published on February 10, 2026 [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which will last until December 31, 2028 [1] - The procurement volume will be based on the demand reported by medical institutions, with pricing determined by a tiered selection process [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798.19 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is around RMB 550.45 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it is expected to further increase product sales, enhance market share, and improve the company's brand image, positively impacting future business development [2]

Core Viewpoint - The company has received marketing authorization for injectable bivalirudin from the Therapeutic Goods Administration (TGA) of Australia, indicating its capability to sell the product in Australia, which is expected to positively impact the company's overseas market expansion and performance [1][2]. Group 1: Product Information - Product Name: Injectable Bivalirudin [1] - Dosage Form: Injection [1] - Specification: 250mg [1] - Indication: Used as an anticoagulant for patients with high-risk acute coronary syndrome (ACS) undergoing early invasive treatment and those receiving percutaneous coronary intervention (PCI) [1]. Group 2: Regulatory Approvals and Milestones - In January 2019, the company received a drug registration certificate from the National Medical Products Administration (NMPA) for injectable bivalirudin [2]. - In May 2019, the company obtained a GMP certificate from the Hainan Provincial Drug Administration for the active pharmaceutical ingredient [2]. - In June 2019, the company successfully challenged the patent of the original holder of injectable bivalirudin [2]. - In October 2019, the ANDA for injectable bivalirudin received final approval from the FDA, leading to its market launch in the U.S. in 2020 [2]. - In December 2022, injectable bivalirudin passed the consistency evaluation for generic drug quality and efficacy by the NMPA [2]. - In February 2024, the product received registration approval from the Saudi Food and Drug Authority (SFDA) [2]. Group 3: Company Strategy and Product Portfolio - The company has extensive experience in the research, registration, production, and marketing of chemically synthesized peptide drugs, having developed multiple products including injectable thymosin alpha-1 and various other therapeutic drugs [3]. - The internationalization strategy aims to obtain drug approvals and market sales in developed countries such as the U.S. and EU to increase revenue and profit [3].